# Endocannabinoid Control of Microglia Activation as a New Therapeutic Target in the Treatment of Schizophrenia

> **NCT02932605** · NA · COMPLETED · sponsor: **UMC Utrecht** · enrollment: 32 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Placebo
- **DRUG:** Cannabidiol

## Key facts

- **NCT ID:** NCT02932605
- **Lead sponsor:** UMC Utrecht
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-03
- **Primary completion:** 2020-01-31
- **Final completion:** 2020-01-31
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2020-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02932605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02932605, "Endocannabinoid Control of Microglia Activation as a New Therapeutic Target in the Treatment of Schizophrenia". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT02932605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*